OAF1 Antibody

OAS1 Antibody: Role in Cancer and Immunology

OAS1 is an interferon-stimulated gene (ISG) involved in antiviral responses and tumor immunity. Recent studies highlight its prognostic and immunological significance in pan-cancer analyses .

Key Research Findings:

• Prognostic Value:

  • High OAS1 expression correlates with poor survival outcomes in liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), and head and neck squamous cell carcinoma (HNSC) .

  • Conversely, elevated OAS1 levels are associated with favorable prognoses in breast invasive carcinoma (BRCA) and kidney renal clear cell carcinoma (KIRC) .

• Immune Microenvironment:

  • OAS1 expression positively correlates with immune infiltration scores (stromal, immune, and ESTIMATE scores) in most cancers, indicating its role in tumor-immune interactions .

  • Strong associations with M2 macrophage infiltration (pro-tumorigenic) were observed in PAAD, LIHC, HNSC, and BRCA (e.g., CD163 co-expression: R = 0.66 in PAAD) .

• Therapeutic Potential:

  • OAS1 outperformed standard models in predicting immunotherapy efficacy in melanoma (AUC = 0.75) .

Data Table: OAS1 Expression and Prognosis in Selected Cancers

OBF-1 Antibody: Role in B Cell Differentiation

OBF-1 (Oct-Binding Factor 1) is a transcriptional coactivator critical for antibody-secreting cell (ASC) differentiation .

Key Research Findings:

• Genetic Regulation:

  • OBF-1 deficiency blocks ASC differentiation by failing to induce Blimp-1/prdm1 and repress bcl-6, Pax5, and AID .

  • Loss of OBF-1 reduces Syndecan-1+ plasma cells by >90% in T cell-dependent cultures but not in T cell-independent conditions .

• Functional Impact:

  • IgM secretion remains near-normal in OBF-1−/− ASCs, but IgG1 production is impaired, suggesting isotype-specific regulatory roles .

Data Table: OBF-1 Dependency in B Cell Differentiation

Anti-NGF Antibodies: Therapeutic Applications

While unrelated to OAF1, monoclonal antibodies targeting nerve growth factor (NGF) demonstrate clinical relevance in pain management .

Key Research Findings:

• DS002 (Anti-NGF mAb):

  • Phase I trials showed favorable safety (t½ = 176–294 hours) and no immunogenicity in healthy subjects .

  • Preclinical efficacy in osteoarthritis (OA) pain and cancer pain models .

• Efficacy in OA:

  • Anti-NGF antibodies (e.g., tanezumab) significantly reduce WOMAC pain scores (SMD = -0.31) and improve physical function (SMD = -0.36) .

Data Table: Anti-NGF Antibody Clinical Outcomes

Observed Antibody Space (OAS): A Resource for Antibody Mining

The OAS database catalogs over 2.4 billion antibody sequences, enabling large-scale analysis of immune repertoires .

Key Features:

• Data Diversity: Includes paired/unpaired sequences from 80+ studies, covering humans, mice, and disease states (e.g., HIV, cancer) .

• Applications: Supports antibody engineering, vaccine design, and biomarker discovery .